Pradaxa (dabigatran etexilate) - Important Safety Information from Boehringer Ingelheim as approved by the Irish Medicines Board 04.11.2011

Notice type: 3rd Party Publications

Date: 04/11/2011

 

Problem Or Issue:
Important Safety Information communication from Boehringer Ingelheim on the importance of assessing renal function in patients treated with Pradaxa (dabigatran etexilate).

Important Safety Information - Pradaxa


« Back